IN2015DN01786A - - Google Patents

Info

Publication number
IN2015DN01786A
IN2015DN01786A IN1786DEN2015A IN2015DN01786A IN 2015DN01786 A IN2015DN01786 A IN 2015DN01786A IN 1786DEN2015 A IN1786DEN2015 A IN 1786DEN2015A IN 2015DN01786 A IN2015DN01786 A IN 2015DN01786A
Authority
IN
India
Prior art keywords
subject
pronucleotide
administering
formula
need
Prior art date
Application number
Inventor
P Iyer Radhakrishnan
Padmanabhan Seetharamaiyer
Original Assignee
Spring Bank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank filed Critical Spring Bank
Publication of IN2015DN01786A publication Critical patent/IN2015DN01786A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A method for treating HBV in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a pronucleotide according to Formula (I):
IN1786DEN2015 2005-12-13 2006-12-13 IN2015DN01786A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs
PCT/US2006/047617 WO2007070598A2 (en) 2005-12-13 2006-12-13 Nucleotide and oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
IN2015DN01786A true IN2015DN01786A (en) 2015-07-10

Family

ID=38194676

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1786DEN2015 IN2015DN01786A (en) 2005-12-13 2006-12-13

Country Status (17)

Country Link
US (6) US8076303B2 (en)
EP (3) EP3090748B1 (en)
JP (1) JP5044854B2 (en)
KR (2) KR101248873B1 (en)
CN (2) CN101437397B (en)
CY (2) CY1117576T1 (en)
DK (2) DK3090748T3 (en)
ES (2) ES2729657T3 (en)
HR (1) HRP20160531T1 (en)
HU (2) HUE029190T2 (en)
IN (1) IN2015DN01786A (en)
LT (1) LT3090748T (en)
PL (2) PL3090748T3 (en)
PT (1) PT3090748T (en)
RS (1) RS54867B1 (en)
SI (2) SI1968612T1 (en)
WO (1) WO2007070598A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292973T1 (en) * 2001-01-16 2005-04-15 Can Fite Biopharma Ltd USE OF AN ADENOSINE A3 RECEPTOR AGONIST TO INHIBIT VIRUS REPLICATION
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
KR101806314B1 (en) 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. Compositions and methods for treating viral infections
WO2010039543A2 (en) * 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CN102307889A (en) * 2008-12-23 2012-01-04 集润德斯股份公司 Sulfurizing reagents and their use for oligonucleotides synthesis
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
IN2012DN00720A (en) * 2009-07-06 2015-06-19 Ontorii Inc
CN101659612B (en) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 Selective esterification method
WO2012030626A2 (en) * 2010-08-30 2012-03-08 Spring Bank Pharmaceuticals, Inc. Design of oligonucleotide analogs as therapeutic agents
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
CN103796657B (en) 2011-07-19 2017-07-11 波涛生命科学有限公司 The method for synthesizing functionalization nucleic acid
KR101327026B1 (en) 2011-11-29 2013-11-13 현대자동차주식회사 Protective of automobile driver
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
ES2940887T3 (en) 2012-07-13 2023-05-12 Wave Life Sciences Ltd Chiral Oligonucleotide Preparation Method
EP2956145A4 (en) * 2013-02-18 2016-08-17 Spring Bank Pharmaceuticals Inc Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
SG10201912897UA (en) * 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
WO2016045642A1 (en) * 2014-09-28 2016-03-31 National Institute Of Biological Sciences, Beijing Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
WO2016164625A1 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
CA2991156A1 (en) * 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
EP3426671A4 (en) * 2016-03-11 2019-11-20 Spring Bank Pharmaceuticals, Inc. Compounds and compositions for the treatment of infections
WO2018013908A1 (en) * 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
JOP20170192A1 (en) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (en) 2017-04-28 2020-02-19 Novartis Ag ANTIBODY CONJUGATES INCLUDING A STING AGONIST
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds compositions, and methods for the treatment of disease
CN110467646A (en) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 Dinucleotide pro-drug
CN110467647B (en) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 Process for preparing dinucleotide prodrug
WO2019219070A1 (en) * 2018-05-18 2019-11-21 正大天晴药业集团股份有限公司 Deuterated oligonucleotide and prodrug
MX2020012964A (en) 2018-06-01 2021-02-16 Eisai R&D Man Co Ltd Methods for the treatment of bladder cancer.
FR3082434B1 (en) 2018-06-14 2021-04-30 Cairdac AUTONOMOUS "CAPSULE LEADLESS" CARDIAC IMPLANT, INCLUDING AN ENERGY RECOVERY WITH PIEZOELECTRIC BLADE
JP6767589B1 (en) 2018-08-16 2020-10-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Salts of compounds and their crystals
JP2022509929A (en) 2018-10-31 2022-01-25 ノバルティス アーゲー DC-SIGN antibody conjugate containing STING agonist
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
CN113164506B (en) * 2018-12-06 2023-12-08 正大天晴药业集团股份有限公司 Dinucleotide compounds and prodrugs thereof
CN111484540B (en) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 Compounds containing dinucleotide structures
CN111484541B (en) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 Dinucleotide prodrugs and methods of making same
JP7421280B2 (en) 2019-07-30 2024-01-24 三和シヤッター工業株式会社 fittings

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041A1 (en) 1978-04-19 1979-10-31 Reich Maschf Gmbh Karl METHOD AND DEVICE FOR DIVIDING PANELS
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
ATE193890T1 (en) 1990-04-18 2000-06-15 Procter & Gamble Pharma ANTIMICROBIAL QUINOLONYL LACTAMES
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2705099B1 (en) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Phosphorothioate triester oligonucleotides and process for their preparation.
FR2709754B1 (en) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Compounds 2 'or 3'-deoxy- and 2', 3'-dideoxy-beta-L-pentofuranonucleosides, preparation process and therapeutic application, in particular anti-viral.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
JP4294870B2 (en) 1998-08-10 2009-07-15 インデニックス ファーマシューティカルズ リミティド Β-L-2'-deoxy-nucleoside for the treatment of hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20040018150A1 (en) 2000-07-21 2004-01-29 Becker Mark W. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
KR100991975B1 (en) * 2001-05-16 2010-11-04 미게닉스 인코포레이티드 Nucleic acid-based compounds and methods of use thereof
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (en) 2006-09-15 2011-04-20 华为技术有限公司 Random access method and system for new access nodes
KR101806314B1 (en) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. Compositions and methods for treating viral infections

Also Published As

Publication number Publication date
KR101123534B1 (en) 2012-03-13
HUE044034T2 (en) 2019-09-30
SI1968612T1 (en) 2016-10-28
HRP20160531T1 (en) 2016-08-12
KR20110125677A (en) 2011-11-21
CN101437397A (en) 2009-05-20
EP1968612B1 (en) 2016-03-09
US20070149462A1 (en) 2007-06-28
KR20080072084A (en) 2008-08-05
CY1117576T1 (en) 2017-04-26
LT3090748T (en) 2019-08-26
RS54867B1 (en) 2016-10-31
WO2007070598A8 (en) 2008-12-31
US20200087338A1 (en) 2020-03-19
PL3090748T3 (en) 2020-03-31
US20160060287A1 (en) 2016-03-03
HUE029190T2 (en) 2017-02-28
CN102796155B (en) 2015-08-26
US20140323554A1 (en) 2014-10-30
WO2007070598A9 (en) 2007-11-08
EP1968612A4 (en) 2013-01-09
PL1968612T3 (en) 2016-11-30
US20120264709A1 (en) 2012-10-18
EP3090748B1 (en) 2019-02-20
US8076303B2 (en) 2011-12-13
US20180273574A1 (en) 2018-09-27
KR101248873B1 (en) 2013-04-02
JP5044854B2 (en) 2012-10-10
US10344046B2 (en) 2019-07-09
WO2007070598A2 (en) 2007-06-21
CN102796155A (en) 2012-11-28
JP2009519345A (en) 2009-05-14
SI3090748T1 (en) 2019-09-30
ES2573928T3 (en) 2016-06-13
WO2007070598A3 (en) 2008-10-30
EP3553072A1 (en) 2019-10-16
CN101437397B (en) 2012-09-05
EP1968612A2 (en) 2008-09-17
US10047114B2 (en) 2018-08-14
DK3090748T3 (en) 2019-05-27
EP3090748A1 (en) 2016-11-09
CY1121639T1 (en) 2020-07-31
ES2729657T3 (en) 2019-11-05
PT3090748T (en) 2019-06-04
US8691787B2 (en) 2014-04-08
DK1968612T3 (en) 2017-05-22

Similar Documents

Publication Publication Date Title
IN2015DN01786A (en)
EA201300860A1 (en) CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS
MX2009003727A (en) Boronic acids and esters as inhibitors of fatty amide hydrolase.
MX2009008439A (en) Novel inhibitors hepatitis c virus replication.
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
ATE511835T1 (en) BIOPHOSPHONATES FOR THE TREATMENT OF ENDOMETRIOSIS
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200806299A (en) Treatment of pain
RU2010144637A (en) SUBSTITUTED GAMMA-LACTAMS AS THERAPEUTIC AGENTS
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
ATE537175T1 (en) NEW PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES
IL198901A0 (en) Pyrimidine derivatives and multiple myeloma
MX2013014938A (en) Compounds for the treatment of addiction.
EP2671891A3 (en) Ang-2 inhibition to treat multiple sclerosis
MY150903A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
TW200639159A (en) Treatment of pain
MX2009009238A (en) Novel phosphodi esterase inhibitors.
PL2099769T3 (en) 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
SE0501903L (en) Boron compounds useful at BNCT
TNSN08506A1 (en) Substituted carboxamides
MX2011012068A (en) 2'-fluoro arabino nucleosides and use thereof.
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis